NDAOPHTHALMICGEL
Approved
Feb 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
10
Data completeness
7/8 — Comprehensive
LOTEMAX SM (loteprednol etabonate) by Bausch + Lomb is corticosteroid. Approved for ocular inflammation, cataract surgery, pain and 1 more indications. First approved in 2019.
Drug data last refreshed 23h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOTEMAX SM is an ophthalmic gel formulation of loteprednol etabonate, a corticosteroid approved by the FDA in February 2019. It is indicated for the treatment of post-operative inflammation and pain following ocular surgery. The drug works by inhibiting the inflammatory response through multiple mechanisms, including suppression of prostaglandin production and inhibition of edema, fibrin deposition, capillary dilation, and leukocyte migration. As a topical ophthalmic corticosteroid, it represents a localized treatment approach for post-surgical ocular inflammation.
$0.0BPart D
10.6 years to LOEMechanism of Action
corticosteroid. Corticosteroids have been shown to inhibit the inflammatory response to a variety of inciting agents. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation…
Indications (4)
Worked on LOTEMAX SM at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.